These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38824645)

  • 1. Comparison between screening for primary aldosteronism with and without drug adjustment.
    Hua Y; He Q
    Blood Press; 2024 May; 33(1):2350981. PubMed ID: 38824645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical recommendations for antihypertensive therapy during the primary aldosteronism screening test.
    Li J; Yan H; Li L; Lin X; Zhao Z; Zhou C; Zhang Q
    Endocrine; 2024 Jan; 83(1):188-195. PubMed ID: 37924464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
    Browne GA; Griffin TP; O'Shea PM; Dennedy MC
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aldosterone-to-renin ratio threshold for screening primary aldosteronism in Chinese hypertensive patients].
    Chen SX; Du YL; Zhang J; Gong YC; Hu YR; Chu SL; He QB; Song YY; Zhu DL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):868-72. PubMed ID: 17217708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
    Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
    Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How should anti-hypertensive medications be adjusted before screening for primary aldosteronism?
    Lu JY; Chang YY; Lee TW; Wu MH; Chen ZW; Huang YT; Lai TS; Er LK; Lin YH; Wu VC; Cheng HM; Kao HL; Jia-Yin Hou C; Wu KD; Chen ST; Liu FH
    J Formos Med Assoc; 2024 Mar; 123 Suppl 2():S91-S97. PubMed ID: 37291044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroidomics-Based Screening for Primary Aldosteronism: Impact of antihypertensive Drugs.
    Constantinescu G; Gruber S; Fuld S; Peitzsch M; Schulze M; Remde H; Kürzinger L; Yang J; Yen T; Williams TA; Müller L; Reincke M; Lenders JWM; Beuschlein F; Pamporaki C; Eisenhofer GF
    Hypertension; 2024 Oct; 81(10):2060-2071. PubMed ID: 39082132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cutoff value of aldosterone-to-renin ratio for the diagnosis of primary aldosteronism in patients taking antihypertensive medicine.
    Niizuma S; Nakahama H; Kamide K; Fukuchi K; Iwanaga Y; Nakata H; Yoshihara F; Horio T; Nakamura S; Kawano Y
    Clin Exp Hypertens; 2008 Oct; 30(7):640-7. PubMed ID: 18855267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication.
    Seiler L; Rump LC; Schulte-Mönting J; Slawik M; Borm K; Pavenstädt H; Beuschlein F; Reincke M
    Eur J Endocrinol; 2004 Mar; 150(3):329-37. PubMed ID: 15012618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of aging on the diagnosis of primary aldosteronism.
    Nakama C; Kamide K; Kawai T; Hongyo K; Ito N; Onishi M; Takeya Y; Yamamoto K; Sugimoto K; Rakugi H
    Hypertens Res; 2014 Dec; 37(12):1062-7. PubMed ID: 25164207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study.
    Jaffe G; Gray Z; Krishnan G; Stedman M; Zheng Y; Han J; Chertow GM; Leppert JT; Bhalla V
    Hypertension; 2020 Mar; 75(3):650-659. PubMed ID: 32008436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism.
    Trenkel S; Seifarth C; Schobel H; Hahn EG; Hensen J
    Exp Clin Endocrinol Diabetes; 2002 Apr; 110(2):80-5. PubMed ID: 11928071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of plasma aldosterone and renin data between an automated chemiluminescent immunoanalyzer and conventional radioimmunoassays in the screening and diagnosis of primary aldosteronism.
    Tamura N; Watanabe E; Shirakawa R; Nakatani E; Yamada K; Hatakeyama H; Torii-Hanakita M; Kyo C; Kosugi R; Ogawa T; Kotani M; Usui T; Inoue T
    PLoS One; 2021; 16(7):e0253807. PubMed ID: 34242264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Ramipril on the Aldosterone/Renin Ratio and the Aldosterone/Angiotensin II Ratio in Patients With Primary Aldosteronism.
    Guo Z; Poglitsch M; Cowley D; Domenig O; McWhinney BC; Ungerer JPJ; Wolley M; Stowasser M
    Hypertension; 2020 Aug; 76(2):488-496. PubMed ID: 32507039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for primary aldosteronism in a primary care unit.
    Volpe C; Wahrenberg H; Hamberger B; Thorén M
    J Renin Angiotensin Aldosterone Syst; 2013 Sep; 14(3):212-9. PubMed ID: 23118039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives.
    Rossi E; Regolisti G; Negro A; Sani C; Davoli S; Perazzoli F
    Am J Hypertens; 2002 Oct; 15(10 Pt 1):896-902. PubMed ID: 12372677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of primary aldosteronism diagnosis in initial evaluation without medication withdrawal or confirmatory tests.
    Ruiz-Sánchez JG; Fernández Sánchez Á; Meneses D
    Endocrine; 2024 Aug; 85(2):906-915. PubMed ID: 38568364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a diagnostic model for pre-washout screening of primary aldosteronism.
    Wang Q; Dong H; Li HW; Zheng ZH; Liu YZ; Hua YH; Xiong YJ; Zhang HM; Song L; Zou YB; Jiang XJ
    J Endocrinol Invest; 2024 Oct; 47(10):2539-2550. PubMed ID: 38536656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.
    Lamarre-Cliche M; de Champlain J; Lacourcière Y; Poirier L; Karas M; Larochelle P
    Am J Hypertens; 2005 Jan; 18(1):56-64. PubMed ID: 15691618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.